Skip to content
Biodatica
Start free

Regeneron Pharmaceuticals

Duarte, California

OncologyPhase IIIListed · REGN

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

1w agoTrial registeredJul 8, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Dec 11, 2024

    Relapsed/Refractory Multiple Myeloma · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT06669247 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    Aug 7, 2024

    Relapsed/Refractory Systemic Light Chain Amyloidosis · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

    ClinicalTrials.gov · NCT06292780 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Feb 15, 2024

    B-Cell Non-Hodgkin Lymphoma (B-NHL) · ACTIVE_NOT_RECRUITING · sponsor: Regeneron Pharmaceuticals · A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

    ClinicalTrials.gov · NCT06230224 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Dec 12, 2023

    Follicular Lymphoma (FL) · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

    ClinicalTrials.gov · NCT06091254 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Sep 18, 2023

    Relapsed Refractory Multiple Myeloma (RRMM) · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT05730036 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Apr 20, 2023

    B-cell Non-Hodgkins Lymphoma (B-NHL) · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

    ClinicalTrials.gov · NCT05685173 (opens the source filing in a new tab)

  7. Trial

    PHASE1 registered

    Aug 17, 2022

    Multiple Myeloma · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    ClinicalTrials.gov · NCT05137054 (opens the source filing in a new tab)

  8. Trial

    PHASE2 registered

    Nov 13, 2019

    B-cell Non-Hodgkin Lymphoma (B-NHL) · ACTIVE_NOT_RECRUITING · sponsor: Regeneron Pharmaceuticals · A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

    ClinicalTrials.gov · NCT03888105 (opens the source filing in a new tab)

  9. Trial

    PHASE1 registered

    Jan 11, 2016

    Relapsed/Refractory Aggressive B-Cell Lymphoma · COMPLETED · sponsor: Regeneron Pharmaceuticals · A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

    ClinicalTrials.gov · NCT02651662 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources